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This special issue of ‘Nanomedicine’ was compiled after the 3rd International Conference on 
Nanotechnology in Medicine, held in Manchester, United Kingdom, in November 2015. It brought 
together international scientists and clinicians from multidisciplinary backgrounds and specialities to 
share a common interest in pushing the boundaries of our current understanding of the field of 
nanomedicine. The focus of this special issue is on key areas in the application of nanotechnology, 
with the aim of highlighting recent advances and developments to realise the full potential of 
Nanomedicine. 
A key application of nanotechnology in medicine that has gained a plethora of interest is in targeted 
drug delivery. While Feczko and colleagues illustrate the potential use of IFN-alpha drug loaded 
nanocomposites as a potential tool for intravenous controlled release drug delivery, Quignard and 
colleagues formulated nanometric oil droplets for encapsulating solid nanoparticles as a way of 
modulating their internalisation pathway and enhance intracellular delivery. An important 
advancement in the area of drug delivery is triggered response nanoparticulate systems. These 
include the use of a bio-inspired mineralisation process and superparmagnetic hybride nanobeads. 
The work by Campodoni and colleagues provides a good example of performing such magnetic 
functionality. They synthesised superparamagnetic hybrid nanobead hydroxyapatite composite 
material as a drug carrier system, with the ability of remote activation by a magnetic signal. This 
unique multifunctional drug delivery system is bioresorbable and biocompatible, holding promise for 
smart applications in nanomedicine, including active targeting and therapeutic purposes. An 
emergent technology in inhalation therapy is the use of targeted liposomes, which has the potential 
of improving pulmonary delivery of drugs such as corticosteroids for patients with chronic asthma. 
Altube and colleagues synthesised pH sensitive archaeosomes, which are lipid vesicles extracted 
from archaebacterial that have the property of resistance to lipolytic enzymes. These were loaded 
with Dexamethasome as a model drug. The resultant nanoliposomes exhibited new 
pharmacodynamics properties with increased mechanical properties during nebulisation, 
highlighting the potential of this novel concept. 
Another key application of nanotechnology in medicine, enabled by advances in targeted drug 
delivery, is in therapeutics, in particular, cancer therapy. The review article by karponis and 
colleagues illustrates the theranostic properties of magnetic nanoparticles, as a promising candidate 
for the targeting and treatment of cancer. This work was presented as a keynote lecture at the 
conference. Other nanoparticles, in particular, gold nanoparticles, also show significant potential as 
theranostic agents, which integrate both diagnostic and therapeutic properties. Butterworth and 
colleagues, illustrate clearly this concept in the simultaneous diagnosis and therapy of prostate 
cancer. Using thiol stabilised gold nanoparticles, the authors were able to demonstrate enhanced CT 
image contrast and increased radiosensitivity of prostate tumours. This study represents one of the 
first examples of successful in vivo radiosensitisation, combined by CT enhancement, in prostate 
cancer. Agrawarl and colleagues describe the use of PEGylated chitosan nanoparticles as a delivery 
system for breast cancer therapy, to potentiate the anticancer activity of Ormeloxifene. The work 
was supported by in vivo pharmacokinetic and pharmacodynamics studies, to demonstrate the 
significant improvement in therapeutic potential of the drug. The work by Afzal and colleagues 
highlights the potential of a folate-based strategy as a targeted delivery system for cancer therapy. 
Using Docetaxel as a model drug and tumour regression studies, they were able to demonstrate the 
superiority of folate as a targeting ligand, over PEGylation and other labelling strategies. 
Other emerging applications of nanotechnology in medicine, is their huge potential in diagnostics for 
the detection of biomarkers and pathogens. These include the use of biosensors for the detection of 
analytes within solutions and body fluids. For example, Si Nanowire field effect transistor (FET) 
biosensors represent highly sensitive analytical devices that enable real time detection of a range of 
molecular markers. Dmitrienko and colleagues propose a novel type of surface modification of the 
biosensor surface for highly specific detection of short RNAs for the early diagnosis of cancer and 
monitoring of disease progression. Alatraktchi and colleagues demonstrate the application of 
nanotechnology in the rapid detection of pathogens. The authors highlight the superiority of 
amperometry for the detection of pathogen markers and their superiority over standard 
spectrophotometric techniques, as a direction towards point of care for the diagnosis of bacterial 
infections. Other applications of nanotechnology in combating infections include the development of 
a prototype catheter dressing which incorporates particles of Chlorhexidine hexametaphosphate. 
These form a nanoparticulate salt at the catheter entry site to inhibit bacterial growth and reduce 
wound colonisation, as demonstrated by the work of Barbour and colleagues. Such compounds may 
have great future potential as useful components in would care materials to control infections. 
Whilst the potential use of nanoparticles in cancer therapy and diagnostics is clearly realised, Shukur 
and colleagues, illustrate the dosage dependent influence of nanoparticles on arterial function, 
which highlights the need to assess nanomaterial biocompatibility for maintaining vasodilation 
(hence organ perfusion) when administered intravenously and help identify strategies for their safe 
clinical administration. Finally, the review article by Sivakumaran and colleagues highlights the 
paramount importance for accurate characterisation of nanomaterials that are used in clinical 
diagnosis and therapeutics, in order to realise the full potential of Nanotechnology in Medicine. The 
authors explore a range of analytic techniques and measurement modalities for studying the 
physicochemical characteristics of nanomaterials and discuss the potential of a recent advancement 
in technology, which combines therapeutics and diagnostic applications, namely Tunable Resistive 
Pulse Sensing (TRPS). The tool enables a range of applications, including their use as a tool in the 
rapidly expanding field of exosome research and in the evaluation of interactions between 
nanomaterials and components of body fluids, which is key to evaluating their fate after systemic 
administration. 
 
To conclude, Nanomedicine is a rapidly expanding field, with continually emerging novel 
technologies.  We look forward to the continued sharing of knowledge and expertise by a 
multidisciplinary team of scientists and clinicians to address key challenges and debates at the 
forthcoming 4th international conference of Nanotechnology in Medicine, to be held in Warsaw, in 
November 2016. 
 
